Moderna and Recipharm Announce COVID-19 Vaccine Supply Agreement
The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
Moderna and Recipharm announced on Dec. 30, 2020 that they have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
According to a Recipharm press release, the manufacturing will take place at Recipharm’s drug product manufacturing facility in France and, subject to regulatory approval in countries outside of the US, the supply will begin in early 2021.
“We are making important progress in the development of the Moderna COVID-19 vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, senior vice-president, International Manufacturing, Moderna, in the press release. “We look forward to their support in the delivery of our vaccine to market.”
“This is a material and strategically important agreement for us, and we are delighted to be working with Moderna on such a vital project to support the long-term fight against COVID-19,” said Thomas Eldered, CEO of Recipharm, in the press release. “Our preparations are already well underway with the hiring of new staff and investment in the facility to enable us to meet the challenging timelines.”
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
